December 10, 2019
Kissei Pharmaceutical’s GnRH receptor antagonist linzagolix demonstrated positive results in a PIII study in patients with uterine fibroids, the drug’s licensee ObsEva of Switzerland said on December 9. The PIII trial, named PRIMROSE 2, investigated the efficacy of once-daily oral...read more